Gilead Sciences (NASDAQ:GILD) Insider Sells $371,760.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

• On Friday, May 15th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00.
• On Wednesday, April 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00.

Gilead Sciences Stock Up 2.4%

Shares of NASDAQ:GILD traded up $2.93 during trading on Tuesday, reaching $127.23. 9,381,571 shares of the stock traded hands, compared to its average volume of 7,008,783. The stock has a 50-day moving average of $132.86 and a two-hundred day moving average of $134.32. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a market cap of $157.96 billion, a P/E ratio of 17.33 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the company posted $1.81 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently modified their holdings of GILD. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after buying an additional 26,882 shares in the last quarter. Aviva PLC increased its holdings in Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after buying an additional 59,782 shares in the last quarter. NewEdge Wealth LLC increased its holdings in Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after buying an additional 17,284 shares in the last quarter. Nordea Investment Management AB increased its holdings in Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after buying an additional 726,101 shares in the last quarter. Finally, Life Cycle Investment Partners Ltd purchased a new position in Gilead Sciences in the fourth quarter valued at $1,418,000. 83.67% of the stock is currently owned by institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s filing for Yeztugo, a potential once-weekly oral HIV prevention pill. If approved, it could expand Gilead’s PrEP offering and strengthen its long-term HIV revenue stream. Article Title
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and set a $155 price target, implying meaningful upside from current levels and reinforcing a bullish analyst view on Gilead’s pipeline and earnings outlook.
• Positive Sentiment: Recent commentary also highlighted Gilead’s growing momentum in liver disease after approvals and trial progress in that area, which could diversify growth beyond HIV and improve investor confidence. Article Title
• Neutral Sentiment: The FDA assigned a PDUFA date of February 2, 2027 for Yeztugo, meaning the catalyst is important but still months away, so the near-term impact is limited.
• Negative Sentiment: Gilead shares have recently traded below their 50-day and 200-day moving averages, suggesting the stock still faces technical headwinds despite the latest positive developments.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GILD shares. Argus raised their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Rothschild & Co Redburn dropped their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Mizuho increased their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.